InvestSMART

Syntara Limited (ASX:SNT)

ALERT: Price-sensitive ASX Announcement for SNT
Current share price for SNT : $0.027 0.005 (20.45%)+
Announcement
Release
27 Jul 2026 9:18AM
Price at Release
$0.022
Full Release
download
Summary
Syntara Limited's quarterly report for the period ended 30 June 2026 highlights significant developments in clinical trials, financial activities, and cash flow management. The company received positive feedback from the US FDA for its proposed Phase 2b trial of amsulostat for myelofibrosis. Syntara secured an $8 million institutional placement, extending its cash runway to Q3 2027, and reported preliminary positive results from its SNT-4728 trial for Parkinson’s disease-related inflammation. The company's cash and cash equivalents at the quarter's end stood at $13.5 million, a substantial increase from the previous quarter, largely due to successful capital raising efforts. The report also detailed cash flows from operating, investing, and financing activities, including significant expenditures on research and development, and payments to related parties.
Key Points
  • Positive FDA feedback supports Phase 2b trial for amsulostat.
  • Secured $8 million institutional placement to strengthen financial position.
  • Preliminary SNT-4728 results show a reduction in Parkinson’s disease-related inflammation.
  • Cash and cash equivalents increased to $13.5 million at the end of the quarter.
  • Continued significant expenditure on research and development.
  • Activities are focused on advancing clinical trials and engaging with potential commercial partners.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.